Mind Medicine (MindMed) (MNMD) - 2023 Q2 - Earnings Call Transcript

On a related note, in June, FDA released draft guidance for developing drugs in psychonomic drug corn. Notably, this guidance highlights the reality that dose response is not well understood to the drug class and It also reinforces our high degree of confidence in our team's ability to launch and enroll future studies in a very efficient manner. Patient dosing enrollment for our Phase 2b trial in GAD is progressing well across our 20 active sites and we expect to complete study enrollment in the third quart ...